封面
市場調查報告書
商品編碼
1795298

全球體內注射器市場

On-Body Injectors

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 177 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球體內注射器市場規模將達到 70 億美元

全球體表注射器市場規模預計在2024年達到41億美元,預計2024年至2030年期間的複合年成長率為9.5%,到2030年將達到70億美元。本報告分析的細分市場之一-電子注射器,預計其複合年成長率將達到11.1%,到分析期結束時規模將達到47億美元。機械注射器細分市場在分析期間的複合年成長率預計為6.7%。

美國市場規模估計為 11 億美元,中國市場預期複合年成長率為 9.1%

美國人體注射器市場規模預估2024年達到11億美元。作為世界第二大經濟體,中國預計到2030年市場規模將達到11億美元,在2024-2030年的分析期間內,複合年成長率為9.1%。其他值得關注的區域市場包括日本和加拿大,預計在分析期間內,這兩個市場的複合年成長率分別為8.9%和7.8%。在歐洲,預計德國市場的複合年成長率約為7.4%。

全球體內注射器市場-主要趨勢與促進因素摘要

為什麼體內注射器會徹底改變藥物傳遞方式

體表注射器 (OBI) 是一種穿戴式式給藥系統,旨在在可控的時間內內皮下注射大量生技藥品或藥物。這些裝置通常佩戴在腹部或手臂上,方便患者在家中自行給藥,減少對醫院輸液和頻繁就診的依賴。體表注射器尤其適用於需要定期給藥的慢性疾病,例如癌症、自體免疫疾病和糖尿病。

以患者為中心、微創且便捷的給藥解決方案的需求日益成長,推動了其應用。 OBI 能夠最大限度地減少給藥不適,且無需患者主動參與,從而提高治療依從性。它們還能輸送高黏度生技藥品,而這些製劑無法使用傳統的預填充式注射器或自動注射器快速注射。這種向穿戴式注射器的轉變與遠端醫療和居家護理的廣泛趨勢相吻合。

設備設計和技術的進步如何改善體內注射器?

技術創新正在透過改進人體工學、安全性和功能性來塑造下一代體表注射器。最新的體表注射器 (OBI) 配備預填充儲藥器、自動針頭插入和回縮裝置,以及用於引導患者的音訊或視覺指示器。一些設備甚至實現了數位連接,可將使用數據傳輸給醫療保健提供者,以實現遠端監控和治療管理。

微型組件、更強的皮膚黏合劑以及整合的壓力感測器和微型幫浦使設備更加隱蔽,佩戴更舒適。藥物輸送現在可以控制在幾分鐘到幾小時內完成,給藥量可達5毫升或更大。與高黏度製劑的兼容性得到改善,也使得單株抗體、荷爾蒙和長效治療藥物(先前僅限於靜脈注射)可以進行皮下給藥。

哪些治療和市場趨勢推動了 OBI 使用的增加?

慢性病的增多和生物製藥的核准,推動了對OBI等患者友善給藥系統的需求。在腫瘤學領域,像Pegfilgrastim這樣的藥物在體內給藥可以實現門診病人治療模式,並降低住院相關的感染風險。在類風濕性關節炎和克隆氏症自體免疫疾病中,OBI可以實現常規生物製藥治療,而無需承受注射帶來的疲勞和奔波負擔。

製藥公司擴大將OBI納入臨床試驗和商業化計劃,共同開發藥械組合產品。監管機構鼓勵這種整合發展,並認知到設備在提高治療依從性方面的作用。此外,付款人和醫療保健系統正在支援家庭管理,以降低住院和輸液中心的成本。這些趨勢正在將OBI的作用從利基生技藥品擴展到更廣泛的慢性病管理。

哪些因素推動了體內注射器市場的成長?

體內注射器市場的成長受到多種因素的推動。慢性病和文明病的增加推動了對長期藥物輸送解決方案的需求。生物製藥(包括高濃度和高黏稠度藥物)的進步推動了對穿戴式輸送平台的需求。患者對自我給藥和家庭治療的偏好加速了 OBI 的採用,尤其是在腫瘤學、免疫學和內分泌學領域。設備設計、安全性和數位整合的技術改進正在推動監管部門的核准和市場滲透。此外,醫療成本壓力和向價值型護理的轉變正在鼓勵製藥和設備公司投資 OBI,以降低治療複雜性、提高依從性並改善患者生活品質。這些因素支持了穿戴式注射器發展和全球市場的強勁勢頭。

部分

類型(電子注射器、機械注射器);疾病(糖尿病、心血管疾病、神經系統疾病、免疫腫瘤疾病、其他疾病);最終用戶(醫院/診所最終用戶、門診手術中心最終用戶、其他最終用戶)

受訪公司範例

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD(Becton, Dickinson & Co.)
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche(Accu-Chek)
  • Sanofi
  • ScPharmaceuticals(ScPharma)
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有查詢通用的 LLM 或特定產業的SLM,而是建立了一個來自世界各地專家的精選內容庫,其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口(成品和原始設備製造商)情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手,包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP37566

Global On-Body Injectors Market to Reach US$7.0 Billion by 2030

The global market for On-Body Injectors estimated at US$4.1 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. Electronic Injectors, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Mechanical Injectors segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.1% CAGR

The On-Body Injectors market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global On-Body Injectors Market - Key Trends & Drivers Summarized

Why Are On-Body Injectors Transforming Drug Delivery Practices?

On-body injectors (OBIs) are wearable drug delivery systems designed to administer large-volume biologics or medications subcutaneously over a controlled period. These devices are typically applied to the abdomen or arm and allow patients to self-administer treatments at home, reducing dependence on hospital-based infusions or frequent clinical visits. On-body injectors are particularly useful for chronic conditions that require regular dosing, such as cancer, autoimmune disorders, and diabetes.

Their adoption is rising due to growing demand for patient-centric, minimally invasive, and convenient drug delivery solutions. OBIs support better treatment adherence by allowing administration with minimal patient discomfort and without active engagement during delivery. They also enable delivery of high-viscosity biologics that cannot be injected rapidly with traditional prefilled syringes or autoinjectors. This shift toward wearable injectors aligns with broader trends in remote care and at-home therapeutics.

How Are Device Design and Technology Advancements Enhancing On-Body Injectors?

Technological innovation is shaping the next generation of on-body injectors through improved ergonomics, safety, and functionality. Modern OBIs feature prefilled drug reservoirs, automatic needle insertion and retraction mechanisms, and audible or visual indicators to guide patients through the process. Some devices offer digital connectivity, enabling transmission of usage data to healthcare providers for remote monitoring and treatment management.

Miniaturization of components, enhanced skin adhesives, and integration of pressure sensors and micro-pumps are making devices more discreet and comfortable to wear. Drug delivery can now be controlled over durations ranging from a few minutes to several hours, allowing administration of volumes up to 5 mL or more. Compatibility with high-viscosity formulations is also improving, enabling subcutaneous delivery of monoclonal antibodies, hormones, and long-acting therapeutics that were previously limited to intravenous routes.

What Therapeutic and Market Trends Are Expanding the Use of OBIs?

Growing prevalence of chronic diseases and biologic drug approvals is driving demand for patient-friendly delivery systems like OBIs. In oncology, on-body delivery of drugs such as pegfilgrastim is enabling outpatient care models and reducing infection risk from clinic visits. In autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, OBIs allow regular biologic therapy without injection fatigue or travel burden.

Pharmaceutical companies are increasingly co-developing drug-device combination products, incorporating OBIs in clinical trials and commercialization plans. Regulatory bodies are encouraging such integrated development, recognizing the role of devices in improving therapy compliance. Additionally, payers and healthcare systems are supporting at-home administration to reduce hospitalization and infusion center costs. These trends are expanding the role of OBIs from niche biologics to broader chronic disease management.

What Factors Are Driving Growth in the On-Body Injectors Market?

Growth in the on-body injectors market is driven by several factors. Rising burden of chronic and lifestyle diseases is increasing demand for long-term drug delivery solutions. Advances in biologic formulations, including high-concentration and high-viscosity drugs, are driving need for wearable delivery platforms. Patient preference for self-administration and at-home treatment is accelerating adoption of OBIs, particularly in oncology, immunology, and endocrinology. Technological improvements in device design, safety, and digital integration are supporting regulatory approvals and market penetration. Additionally, healthcare cost pressures and the shift toward value-based care are encouraging pharmaceutical and device companies to invest in OBIs that reduce treatment complexity, improve adherence, and enhance patient quality of life. These factors collectively support strong momentum in wearable injector development and global market expansion.

SCOPE OF STUDY:

The report analyzes the On-Body Injectors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Electronic Injectors, Mechanical Injectors); Disease (Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease, Other Diseases); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD (Becton, Dickinson & Co.)
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche (Accu-Chek)
  • Sanofi
  • ScPharmaceuticals (ScPharma)
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • On-Body Injectors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Propels Demand for Self-Administered, Long-Acting Drug Delivery Devices
    • Shift Toward Home-Based Care Expands Addressable Market for Wearable and On-Body Injection Systems
    • Growth in Biologics and Large-Molecule Therapies Strengthens Business Case for On-Body Delivery Platforms
    • Increased Focus on Patient Adherence and Convenience Drives Adoption of Hands-Free Injection Devices
    • Advancements in Microelectronics and Battery Technologies Enhance Reliability and Portability of On-Body Injectors
    • Regulatory Support for Connected Health Solutions Spurs Development of Smart On-Body Devices with Monitoring Capabilities
    • Expansion of Subcutaneous Drug Formulations Generates Opportunities for Alternative to In-Clinic Infusion Therapy
    • Integration of Wireless Connectivity and App-Based Interfaces Promotes Real-Time Dose Tracking and Alerts
    • Rising Healthcare Costs and Workforce Shortages Accelerate Use of Automated Injection Systems to Reduce Hospital Dependence
    • Increase in FDA Approvals and CE Marking of Wearable Injectors Boosts Commercial Availability and Market Access
    • Patient-Centric Design Trends Spur Innovation in Painless, Low-Profile On-Body Injection Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World On-Body Injectors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Electronic Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Electronic Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mechanical Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mechanical Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diabetes Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diabetes Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immuno-Oncological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Immuno-Oncological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • JAPAN
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CHINA
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • EUROPE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • FRANCE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • GERMANY
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • UNITED KINGDOM
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ASIA-PACIFIC
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030

IV. COMPETITION